Cantor Fitzgerald analyst William Tanner reiterated a Buy rating on TherapeuticsMD (NYSE MKT: TXMD) yesterday and set a price target of $26. The company’s shares closed yesterday at $5.82.
Tanner noted:
“: We are reiterating our Overweight rating and $26 PT for TXMD stock. Across many dimensions that include safety and efficacy, we believe Imvexxy will become an important new treatment for vulvar vaginal atrophy (VVA), contemporarily referred to as genitourinary syndrome of menopause (GSM). Given the high degree of dissatisfaction with current GSM treatments, we believe Imvexxy could be poised to surprise on the pace of market uptake.”
According to TipRanks.com, Tanner is a 4-star analyst with an average return of 8.7% and a 54.3% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Supernus Pharmaceuticals, and Intra-Cellular Therapies.
Currently, the analyst consensus on TherapeuticsMD is Strong Buy and the average price target is $15.50, representing a 166.3% upside.
In a report issued on May 30, Oppenheimer also reiterated a Buy rating on the stock with a $12 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.01 and a one-year low of $4.04. Currently, TherapeuticsMD has an average volume of 2.7M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Read More on TXMD:
